Last reviewed · How we verify

NCT04449185

Change of Gut Microbiome and Symptom After H.Pylori Eradication Therapy in Patients With Functional Dyspepsia

Status unknown Phase 4 Last updated 26 June 2020
What this trial tests

Phase 4 trial testing Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days in Dyspepsia in 60 participants. Status unknown.

Timeline
30 June 2020
Primary endpoint
30 October 2021
30 October 2021

Quick facts

Lead sponsorAsan Medical Center
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment60
Start date30 June 2020
Primary completion30 October 2021
Estimated completion30 October 2021

Drugs / interventions tested

Conditions studied

Sponsor

Asan Medical Center

Who can join

Adults 18 to 75, any sex, with Dyspepsia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aims of the investigators' study are to investigate the effect of H.pylori eradication on the human gut microbiome and symptoms of functional dyspepsia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Dyspepsia

Currently open trials in the same condition.

Other Asan Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04449185.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing